Spots Global Cancer Trial Database for The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium - Prostate Specific Membrane Antigen (Lu-PSMA)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium - Prostate Specific Membrane Antigen (Lu-PSMA)
Official Title: The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lu-PSMA
Study ID: NCT05208229
Interventions
Study Description
Brief Summary: The role of WB-MRI in the evaluation of prostate cancer patients treated with Lu-PSMA
Detailed Description: Multicentric, observational, single arm, prospective, study. All patients will undergo imaging assessments according to clinical practice or to Lu-PSMA Tumor Institute of Romagna (IRST) 185.03 protocol, as follows: * Baseline, before the treatment with Lu-PSMA, CT and WB-MRI will be performed * At the end of treatment with Lu-PSMA, CT and WB-MRI will be performed * In post-treatment follow-up every 4 months, until progression or for 1 year, CT and WB-MRI will be performed. Patients participating in this observational study will not be subjected to any additional procedure that falls outside the clinical practice or the study 185.03 Lu-PSMA trial at IRST.
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST s.r.l., Meldola, Forlì-Cesena, Italy
European Institute of Oncology, Milan, , Italy
Contact Details
Name: Giovanni Paganelli, MD
Affiliation: IRST IRCCS
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
